CACaterina Anecchino

Caterina Anecchino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Caterina Anecchino has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Gianni Tognoni

    2 shared publications
  • Antonio Nicolucci

    Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy

    1 shared publication
  • Arianna Masciulli

    1 shared publication
  • Caterina Fanizza

    Pharmacoepidemiology laboratory, Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy

    1 shared publication
  • Daniela D'alonzo

    1 shared publication
  • Elisa Rossi

    CINECA Interuniversity Consortium, Bologna, Italy “ARNO project” working group: M Andretta (VR), L Castellani (Bussolengo), M Cecchetto (Bassano), M De Cal (BL), R Di Turi (RM-D), R Gallo (VI), D Garibaldi (LU), AM Grion (PD),M Grossetti (GE), G La Bella (NA-1), F Lena (LI), D Maccari (Pieve di Soligo), C Marinai (FI), M Moruzzo (SP), E Nava (NA-4), A Orsini (TE), B Pari (Chioggia), A Pedrini (Alta padovana), M Rais (Viareggio), G Rizzotti (Adria), MP Cariolato (Ovest Vicentino), MG Zogno (Este)

    1 shared publication

Latest Publications

    • 3 June 2010
      • Vol. 29  (1) , 26-40

    [Memorandum for the management of clinical trials].

    by Miriam Valentini, Maria Celeste Pirozzoli, Daniela D'alonzo, Luisella Pirozzi, Caterina Anecchino, Francesca Tuzi, Marilena Romero, Antonio Nicolucci, Giovanni F M Strippoli, Maurizio Belfiglio, et al.

    A critical appraisal of the recent legislation on clinical trials is proposed, together with some reflections on the implications on the practice and principles of clinical experimentation. The possible role and contribution of Ethical Committees is discussed.

    • 1 December 2007
      • Vol. 2  (4) , 567-574

    Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population

    by Caterina Anecchino, Elisa Rossi, Caterina Fanizza, Marisa De Rosa, Gianni Tognoni, Marilena Romero

    Nowadays, there is increasing awareness about the frequent chronic comorbidities in patients with chronic obstructive pulmonary disease (COPD) but little information is available to quantify the burden of illness that these conditions cause in this population. We aimed to identify and describe a population suffering from COPD highlighting the co-morbid conditions that may contribute to poor clinical outcomes. Epidemiological cross-sectional study conducted using administrative heath services databases. A cohort of 126,283 COPD patients was identified. The estimated prevalence in adult population was 3.6%. Ninety-eight percent of these patients (123,603) received at least one prescription of “non-respiratory drugs” and, considering chronic specific comorbidities (cardiovascular disease, diabetes and depression) 86,351 patients (68.4% of COPD patients) suffered from at least one of these conditions. 80,840 pts (64.4%) were treated for cardiovascular diseases, 17,091 subjects for diabetes (12.4%) and 10,292 for depression (8%). About 16% of COPD subjects (19,168 patients) had two out of the three considered comorbid conditions and 1352 patients (1.1%) all three. This study highlights the complex spectrum of comorbidities in COPD patients. The prevalence of main chronic diseases increases with age, in particular among female group. An enhanced public awareness about these conditions is necessary, just as a more comprehensive approach in their management.